nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

29.03.2024 | Gynecologic Endocrinology and Reproductive Medicine

Assessment of bidirectional relationships between autoimmune diseases and primary ovarian insufficiency: insights from a bidirectional two-sample Mendelian randomization analysis

verfasst von: Rong Luo, Jiahui Wang, Yi Liu

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The simultaneous occurrence of primary ovarian insufficiency (POI) and autoimmune diseases has been noted and debated in some epidemiological research. This bidirectional two-sample Mendelian randomization (MR) study aimed to investigate the causal relationships between autoimmune diseases and POI.

Methods

We obtained summary-level data for ten autoimmune diseases and POI from published large-scale genome-wide association studies and the FinnGen consortium of European ancestry. A series of filtering steps was performed to discern independent genetic variants. Causal estimates were mainly calculated by the inverse variance weighting method and verified through multiple sensitivity analyses.

Results

Of the ten autoimmune diseases, genetically predicted Addison’s disease (odds ratio [OR] = 1.26, 95% confidence interval [CI]: 1.09–1.47, P = 0.003) and systemic lupus erythematosus (OR = 1.12, 95% CI 1.02–1.24, P = 0.021) were associated with an increased risk of POI, and sensitivity analyses confirmed the robustness of the results. In addition, there were weak associations between liability to POI and elevated risks of type 1 diabetes (OR = 1.05, 95% CI 1.00–1.10, P = 0.046) and autoimmune thyroid disease (OR = 1.03, 95% CI 1.01–1.05, P = 0.015).

Conclusion

This study revealed that Addison’s disease and systemic lupus erythematosus are potential risk factors for POI, underscoring the necessity to consider the impact of autoimmune factors in the diagnosis and treatment of POI.

Nur mit Berechtigung zugänglich

Stuenkel CA, Gompel A (2023) Primary ovarian insufficiency. N Engl J Med 388(2):154–163. https://doi.org/10.1056/NEJMcp2116488CrossRefPubMed

Rebar RW, Keator CS (2021) Expanding our knowledge of premature ovarian insufficiency. Fertil Steril 115(2):328–329. https://doi.org/10.1016/j.fertnstert.2020.09.145CrossRefPubMed

Ishizuka B (2021) Current Understanding of the etiology, symptomatology, and treatment options in premature ovarian insufficiency (POI). Front Endocrinol (Lausanne). https://doi.org/10.3389/fendo.2021.626924CrossRefPubMed

Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN et al (2023) Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 401(10391):1878–1890. https://doi.org/10.1016/s0140-6736(23)00457-9CrossRefPubMed

Kirshenbaum M, Orvieto R (2019) Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet 36(11):2207–2215. https://doi.org/10.1007/s10815-019-01572-0CrossRefPubMedPubMedCentral

Ceccarelli F, Orefice V, Perrone G, Pirone C, Perricone C, Truglia S et al (2020) Premature ovarian failure in patients affected by systemic lupus erythematosus: a cross-sectional study. Clin Exp Rheumatol 38(3):450–454PubMed

Grossmann B, Saur S, Rall K, Pecher AC, Hübner S, Henes J et al (2020) Prevalence of autoimmune disease in women with premature ovarian failure. Eur J Contracept Reprod Health Care 25(1):72–75. https://doi.org/10.1080/13625187.2019.1702638CrossRefPubMed

Davies NM, Holmes MV, Davey Smith G (2018) Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. https://doi.org/10.1136/bmj.k601CrossRefPubMedPubMedCentral

Pingault JB, O’Reilly PF, Schoeler T, Ploubidis GB, Rijsdijk F, Dudbridge F (2018) Using genetic data to strengthen causal inference in observational research. Nat Rev Genet 19(9):566–580. https://doi.org/10.1038/s41576-018-0020-3CrossRefPubMed

10.

Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ et al (2021) Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. https://doi.org/10.1136/bmj.n2233CrossRefPubMedPubMedCentral

11.

Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D et al (2018) The MR-Base platform supports systematic causal inference across the human phenome. Elife. https://doi.org/10.7554/eLife.34408CrossRefPubMedPubMedCentral

12.

Eriksson D, Røyrvik EC, Aranda-Guillén M, Berger AH, Landegren N, Artaza H et al (2021) GWAS for autoimmune Addison’s disease identifies multiple risk loci and highlights AIRE in disease susceptibility. Nat Commun 12(1):959. https://doi.org/10.1038/s41467-021-21015-8CrossRefPubMedPubMedCentral

13.

Saevarsdottir S, Olafsdottir TA, Ivarsdottir EV, Halldorsson GH, Gunnarsdottir K, Sigurdsson A et al (2020) FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease. Nature 584(7822):619–623. https://doi.org/10.1038/s41586-020-2436-0CrossRefPubMed

14.

Jiang L, Zheng Z, Fang H, Yang J (2021) A generalized linear mixed model association tool for biobank-scale data. Nat Genet 53(11):1616–1621. https://doi.org/10.1038/s41588-021-00954-4CrossRefPubMed

15.

Liu JZ, van Sommeren S, Huang H, Ng SC, Alberts R, Takahashi A et al (2015) Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 47(9):979–986. https://doi.org/10.1038/ng.3359CrossRefPubMedPubMedCentral

16.

Chia R, Saez-Atienzar S, Murphy N, Chio A, Blauwendraat C (2022) Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc Natl Acad Sci USA. https://doi.org/10.1073/pnas.2108672119CrossRefPubMedPubMedCentral

17.

Cordell HJ, Fryett JJ, Ueno K, Darlay R, Aiba Y, Hitomi Y et al (2021) An international genome-wide meta-analysis of primary biliary cholangitis: novel risk loci and candidate drugs. J Hepatol 75(3):572–581. https://doi.org/10.1016/j.jhep.2021.04.055CrossRefPubMedPubMedCentral

18.

Ishigaki K, Sakaue S, Terao C, Luo Y, Sonehara K, Yamaguchi K et al (2022) Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat Genet 54(11):1640–1651. https://doi.org/10.1038/s41588-022-01213-wCrossRefPubMedPubMedCentral

19.

Bentham J, Morris DL, Graham DSC, Pinder CL, Tombleson P, Behrens TW et al (2015) Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet 47(12):1457–1464. https://doi.org/10.1038/ng.3434CrossRefPubMedPubMedCentral

20.

Chiou J, Geusz RJ, Okino ML, Han JY, Miller M, Melton R et al (2021) Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. Nature 594(7863):398–402. https://doi.org/10.1038/s41586-021-03552-wCrossRefPubMedPubMedCentral

21.

Jin Y, Andersen G, Yorgov D, Ferrara TM, Ben S, Brownson KM et al (2016) Genome-wide association studies of autoimmune vitiligo identify 23 new risk loci and highlight key pathways and regulatory variants. Nat Genet 48(11):1418–1424. https://doi.org/10.1038/ng.3680CrossRefPubMedPubMedCentral

22.

Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C et al (2019) The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res 47(D1):D1005-d1012. https://doi.org/10.1093/nar/gky1120CrossRefPubMed

23.

Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM et al (2023) FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613(7944):508–518. https://doi.org/10.1038/s41586-022-05473-8CrossRefPubMedPubMedCentral

24.

Pierce BL, Ahsan H, Vanderweele TJ (2011) Power and instrument strength requirements for mendelian randomization studies using multiple genetic variants. Int J Epidemiol 40(3):740–752. https://doi.org/10.1093/ije/dyq151CrossRefPubMed

25.

Hemani G, Tilling K, Davey Smith G (2017) Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet 13(11):e1007081. https://doi.org/10.1371/journal.pgen.1007081CrossRefPubMedPubMedCentral

26.

Burgess S, Butterworth A, Thompson SG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 37(7):658–665. https://doi.org/10.1002/gepi.21758CrossRefPubMedPubMedCentral

27.

Bowden J, Davey Smith G, Haycock PC, Burgess S (2016) Consistent estimation in mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 40(4):304–314. https://doi.org/10.1002/gepi.21965CrossRefPubMedPubMedCentral

28.

Bowden J, Davey Smith G, Burgess S (2015) Mendelian randomization with invalid instruments: effect estimation and bias detection through egger regression. Int J Epidemiol 44(2):512–525. https://doi.org/10.1093/ije/dyv080CrossRefPubMedPubMedCentral

29.

Hartwig FP, Davey Smith G, Bowden J (2017) Robust inference in summary data mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol 46(6):1985–1998. https://doi.org/10.1093/ije/dyx102CrossRefPubMedPubMedCentral

30.

Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J (2017) A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med 36(11):1783–1802. https://doi.org/10.1002/sim.7221CrossRefPubMedPubMedCentral

31.

Verbanck M, Chen CY, Neale B, Do R (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet 50(5):693–698. https://doi.org/10.1038/s41588-018-0099-7CrossRefPubMedPubMedCentral

32.

Vogt EC, Breivik L, Røyrvik EC, Grytaas M, Husebye ES, Øksnes M (2021) Primary ovarian insufficiency in women with Addison’s disease. J Clin Endocrinol Metab 106(7):e2656–e2663. https://doi.org/10.1210/clinem/dgab140CrossRefPubMedPubMedCentral

33.

De Bellis A, Bellastella G, Falorni A, Aitella E, Barrasso M, Maiorino MI et al (2017) Natural history of autoimmune primary ovarian insufficiency in patients with Addison’s disease: from normal ovarian function to overt ovarian dysfunction. Eur J Endocrinol 177(4):329–337. https://doi.org/10.1530/eje-17-0152CrossRefPubMed

34.

Reato G, Morlin L, Chen S, Furmaniak J, Smith BR, Masiero S et al (2011) Premature ovarian failure in patients with autoimmune addison’s disease: clinical, genetic, and immunological evaluation. J Clin Endocrinol Metab 96(8):E1255–E1261. https://doi.org/10.1210/jc.2011-0414CrossRefPubMed

35.

Falorni A, Laureti S, Candeloro P, Perrino S, Coronella C, Bizzarro A et al (2002) Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril 78(2):270–279. https://doi.org/10.1016/s0015-0282(02)03205-3CrossRefPubMed

36.

Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, Grymowicz M, Smolarczyk K, Kostrzak A et al (2021) Autoimmune diseases in patients with premature ovarian insufficiency-our current state of knowledge. Int J Mol Sci 22(5):2594. https://doi.org/10.3390/ijms22052594CrossRefPubMedPubMedCentral

37.

Sævik ÅB, Åkerman A-K, Grønning K, Nermoen I, Valland SF, Finnes TE et al (2018) Clues for early detection of autoimmune Addison’s disease – myths and realities. J Internal Med. https://doi.org/10.1111/joim.12699CrossRefPubMed

38.

Crow MK (2023) Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis 82(8):999–1014. https://doi.org/10.1136/ard-2022-223741CrossRefPubMed

39.

Giambalvo S, Garaffoni C, Silvagni E, Furini F, Rizzo R, Govoni M et al (2022) Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. https://doi.org/10.1016/j.autrev.2022.103038CrossRefPubMed

40.

Oktem O, Guzel Y, Aksoy S, Aydin E, Urman B (2015) Ovarian function and reproductive outcomes of female patients with systemic lupus erythematosus and the strategies to preserve their fertility. Obstet Gynecol Surv 70(3):196–210. https://doi.org/10.1097/ogx.0000000000000160CrossRefPubMed

41.

Frangou E, Vassilopoulos D, Boletis J, Boumpas DT (2019) An emerging role of neutrophils and NETosis in chronic inflammation and fibrosis in systemic lupus erythematosus (SLE) and ANCA-associated vasculitides (AAV): Implications for the pathogenesis and treatment. Autoimmun Rev 18(8):751–760. https://doi.org/10.1016/j.autrev.2019.06.011CrossRefPubMed

42.

Lawrenz B, Henes JC, Henes M, Neunhoeffer E, Schmalzing M, Fehm T et al (2011) Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-muellerian hormone. Lupus 20(11):1193–1197. https://doi.org/10.1177/0961203311409272CrossRefPubMed

43.

Medeiros PB, Febrônio MV, Bonfá E, Borba EF, Takiuti AD, Silva CAA (2009) Menstrual and hormonal alterations in juvenile systemic lupus erythematosus. Lupus 18(1):38–43. https://doi.org/10.1177/0961203308094652CrossRefPubMed

44.

Yang W, Lin C, Zhang M, Lv F, Zhu X, Han X et al (2022) Assessment of ovarian reserve in patients with type 1 diabetes: a systematic review and meta-analysis. Endocrine 77(2):205–212. https://doi.org/10.1007/s12020-022-03091-yCrossRefPubMed

45.

Codner E, Merino PM, Tena-Sempere M (2012) Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum Reprod Update 18(5):568–585. https://doi.org/10.1093/humupd/dms024CrossRefPubMed

46.

Atkinson M, Lansdown AJ (2022) Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy. Best Pract Res Clin Endocrinol Metab 36(3):101635. https://doi.org/10.1016/j.beem.2022.101635CrossRefPubMed

47.

Hsieh YT, Ho JYP (2021) Thyroid autoimmunity is associated with higher risk of premature ovarian insufficiency-a nationwide health insurance research database study. Hum Reprod 36(6):1621–1629. https://doi.org/10.1093/humrep/deab025CrossRefPubMed

Titel: Assessment of bidirectional relationships between autoimmune diseases and primary ovarian insufficiency: insights from a bidirectional two-sample Mendelian randomization analysis
verfasst von: Rong Luo
Jiahui Wang
Yi Liu
Publikationsdatum: 29.03.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 6/2024
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-024-07482-6

In vivo measurement of the elastic properties of pelvic floor muscles in pregnancy using shear wave elastography

Maternal-Fetal Medicine

The impact of gender on the self-confidence of practical and surgical skills among OBGYN residents: a trinational survey

Open Access
Maternal-Fetal Medicine

Comparing elective and emergency caesarean section by using bioimpedance method

Maternal-Fetal Medicine

Correction: Effect of swimming exercise on premenstrual syndrome

Correction

Comparison between fascia lata and rectus fascia in treatment of pelvic organ prolapse: a systematic review

Review

Assessment of quality of life, psychological aspects, and sexual function of women with endometriosis according to pain and infertility: a cross sectional study

General Gynecology

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Einer von sieben Frauen macht die Menopause sehr zu schaffen

15.01.2025
Menopause
Nachrichten

Von mäßigen bis schweren vasomotorischen Beschwerden sind 14,7% der Frauen in der Postmenopause betroffen. Das haben kanadische Forscherinnen in einer Subgruppenanalyse der WARM-Studie herausgefunden.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

12.01.2025
Elektronische Patientenakte
Nachrichten

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Keine eingeschränkten Kassenleistungen bei Schwangerschaft nach IVF

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Nach privat bezahlter In-vitro-Fertilisation muss die gesetzliche Krankenkasse ein Arzneimittel zum Erhalt der Schwangerschaft bezahlen, so ein Urteil des Sozialgerichts in München.

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Medikamente in Schwangerschaft und Stillzeit
Nachrichten

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Assessment of bidirectional relationships between autoimmune diseases and primary ovarian insufficiency: insights from a bidirectional two-sample Mendelian randomization analysis